Distinguished in Malignant Mixed Mullerian Tumor

Dr. Ursula A. Matulonis

Oncology
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
Offers Telehealth
Distinguished in Malignant Mixed Mullerian Tumor
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ursula Matulonis is an Oncologist in South Weymouth, Massachusetts. Dr. Matulonis is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Tubal Ligation.

Her clinical research consists of co-authoring 284 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Albany Medical College, 1987
Residency
University of Pittsburgh, Office of GME, 1990
Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Internal Medicine
Medical Oncology
Fellowships
Dana-Farber Cancer Institute, 1993
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Brigham And Women's Faulkner Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Dana-Farber Brigham Cancer Center in clinical affiliation with South Shore Health
101 Columbian Street, South, South Weymouth, MA 02190
Call: 617-632-2334
Other Locations
Dana-Farber Cancer Institute, Gynecologic Oncology Program
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-2334

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 02, 2023
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Pegylated Liposomal Doxorubicin
Study Phase: Phase 2
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 10, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: March 10, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Enrollment Status: Terminated
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

283 Total Publications

Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer.
Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer.
Journal: JAMA network open
Published: September 18, 2025
View All 283 Publications
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Susana Campos
Hematology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Susana Campos
Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susana Campos is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Campos is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, and Malignant Mixed Mullerian Tumor.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Panagiotis A. Konstantinopoulos
Hematology Oncology | Hematology | Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Panagiotis A. Konstantinopoulos
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Panagiotis Konstantinopoulos is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Konstantinopoulos is rated as an Elite provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, and Ovarian Carcinosarcoma. Dr. Konstantinopoulos is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Neil S. Horowitz
Obstetrics and Gynecology | Oncology | Gynecologic Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Neil S. Horowitz
Obstetrics and Gynecology | Oncology | Gynecologic Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3586
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neil Horowitz is an Obstetrics and Gynecologist and an Oncologist in Boston, Massachusetts. Dr. Horowitz is rated as an Elite provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Ovarian Cancer, Vulvar Cancer, Endometrial Cancer, Hysterectomy, and Oophorectomy. Dr. Horowitz is currently accepting new patients.

VIEW MORE MALIGNANT MIXED MULLERIAN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matulonis's expertise for a condition
ConditionClose
  • Elite
  • Endometrial Cancer
    Dr. Matulonis is
    Elite
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
  • Ovarian Cancer
    Dr. Matulonis is
    Elite
    . Learn about Ovarian Cancer.
    See more Ovarian Cancer experts
  • Distinguished
  • Malignant Mixed Mullerian Tumor
    Dr. Matulonis is
    Distinguished
    . Learn about Malignant Mixed Mullerian Tumor.
    See more Malignant Mixed Mullerian Tumor experts
  • Ovarian Carcinosarcoma
    Dr. Matulonis is
    Distinguished
    . Learn about Ovarian Carcinosarcoma.
    See more Ovarian Carcinosarcoma experts
  • Sertoli-Leydig Cell Tumor
    Dr. Matulonis is
    Distinguished
    . Learn about Sertoli-Leydig Cell Tumor.
    See more Sertoli-Leydig Cell Tumor experts
  • Testicular Yolk Sac Tumor
    Dr. Matulonis is
    Distinguished
    . Learn about Testicular Yolk Sac Tumor.
    See more Testicular Yolk Sac Tumor experts
  • Virilizing Ovarian Tumor
    Dr. Matulonis is
    Distinguished
    . Learn about Virilizing Ovarian Tumor.
    See more Virilizing Ovarian Tumor experts
  • Advanced
  • Adult Soft Tissue Sarcoma
    Dr. Matulonis is
    Advanced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Breast Cancer
    Dr. Matulonis is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Pseudomyxoma Peritonei
    Dr. Matulonis is
    Advanced
    . Learn about Pseudomyxoma Peritonei.
    See more Pseudomyxoma Peritonei experts
  • Triple-Negative Breast Cancer
    Dr. Matulonis is
    Advanced
    . Learn about Triple-Negative Breast Cancer.
    See more Triple-Negative Breast Cancer experts
  • Experienced
  • Agranulocytosis
    Dr. Matulonis is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anal Cancer
    Dr. Matulonis is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angiosarcoma
    Dr. Matulonis is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Cervical Cancer
    Dr. Matulonis is
    Experienced
    . Learn about Cervical Cancer.
    See more Cervical Cancer experts
  • Desmoplastic Small Round Cell Tumor
    Dr. Matulonis is
    Experienced
    . Learn about Desmoplastic Small Round Cell Tumor.
    See more Desmoplastic Small Round Cell Tumor experts
  • Inflammatory Breast Cancer
    Dr. Matulonis is
    Experienced
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.